Neuroprotective activity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (PAN-811), a cancer therapeutic agent

CNS Drug Reviews

Volumn 12, Issue 1, 2006, Pages 77-90

  Jiang, Zhi Gang ^a   Lebowitz, Michael S ^a   Ghanbari, Hossein A ^a  

^a Panacea Pharmaceuticals Inc   (United States)

Author keywords

3 AP; Brain ischemia; Free radical scavengers; Metal chelators; Neuroprotection; PAN 811; Stroke; Triapine

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; CALCIUM; GLUTAMIC ACID; IRON; PAN 811; RIBONUCLEOTIDE REDUCTASE; STAUROSPORINE; VERATRIDINE;

ANEMIA; AREA UNDER THE CURVE; ASTHENIA; BICARBONATE BLOOD LEVEL; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BRAIN CELL; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CALCIUM CELL LEVEL; CANCER THERAPY; CARDIOVASCULAR SYMPTOM; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DIARRHEA; DNA SYNTHESIS; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG STRUCTURE; FEVER; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

ANALGESICS; ANIMALS; BRAIN DISEASES; CELL DEATH; HUMANS; NEOPLASMS; NEURONS; NEUROPROTECTIVE AGENTS; PYRIDINES; THIOSEMICARBAZONES;

EID: 33746535102     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2006.00077.x     Document Type: Review

References (67)

1. Abeysinghe RD, Greene BT, Haynes R, et al. p53-Independent apoptosis mediated by tachpyridine, an anticancer iron chelator. Carcinogenesis 2001;22:1607-1614.
2. Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R. The Ginkgo biloba extract (EGB761) protects hippocampal neurons against cell death induced by β-amyloid. Eur J Neurosci 2000;12:1882-1890.
3. Beckloff GL, Lerner HJ, Frost D, Russo-Alesi FM, Gitomer S. Hydroxyurea (NSC-32065) in biological fluids: Dose-concentration relationship. Cancer Chemother Rep 1965;48:57-58.
4. Bonisch H, Graefe KH, Keller B. Tetrodotoxin-sensitive and -resistant effects of veratridine on the noradrenergic neurone of the rat vas deferens. Naunyn Schmiedeberg's Arch Pharmacol 1983;324:264-270.
5. Booth BA, Donnelly TE Jr, Zettner A, Sartorelli AC. Metabolic effects of zinc in intact cells - comparative studies of zinc chloride and the zinc chelate of kethoxal bis(thiosemicarbazone). Biochem Pharmacol 1971;20:3109-3118.
6. Booth BA, Sartorelli AC. Synergistic interaction of kethoxal bis(thiosemicarbazone) and cupric ions in sarcoma 180. Nature 1966;210:104-105.
7. Callaway JK, Beart PM, Jarrott B, Giardina SF. Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM-36, results in profound inhibition of neuronal apoptosis. Br J Pharmacol 2001;132:1691-1698.
8. Chaston TB, Lovejoy DB, Watts RN, Richardson DR. Examination of the antiproliferative activity of iron chelators: Multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 2003;9:402-414.
9. Chen R-W, Yao C, Lu XCM, et al. PAN-811, a novel neuroprotectant elicits its function in primary neuronal cultures by up-regulating Bcl-2 expression. Neuroscience 135:191-201,2005.
10. Conte V, Uryu K, Fujimoto S, et al. Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J Neurochem 2004;90:758-764.
11. Cory JG, Cory AH, Rappa G, et al. Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem Pharmacol 1994;48:335-344.
12. Cory JG, Sato A. Regulation of ribonucleotide reductase activity in mammalian cells. Mol Cell Biochem 1983;53:257-266.
13. Creasey WA, Agrawal KC, Capizzi RL, Stinson KK, Sartorelli AC. Studies of the antineoplastic activity and metabolism of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones in dogs and mice. Cancer Res 1972;32:565-572.
14. Darnell G, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: The effect of the ligands on molecular targets involved in proliferation. Blood 1999;94:781-792.
15. Feun L, Modiano M, Lee K, et al. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother Pharmacol 2002;50:223-229.
16. Finch RA, Liu M, Grill SP, et al. Triapine (3-aminopyridine-2- carboxaldehyde-thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 2000;59:983-991.
17. Finch RA, Liu MC, Cory AH, Cory JG, Sartorelli AC. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): An inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul 1999;39:3-12.
18. Folbergrova J, Zhao Q, Katsura K, Siesjo BK. N-tert-butyl-α- phenylnitrone improves recovery of brain energy state in rats following transient focal ischemia. Proc Natl Acad Sci USA 1995;92:5057-5061.
19. Gao J, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood 2001;98:842-850.
20. Ghanbari HA, Ghanbari KG, Harris PLR, et al. Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients. Aging Cell 2004;3:41-44.
21. Gil J, Almeida S, Oliveira CR, Rego AC. Cytosolic and mitochondrial ROS in staurosporine-induced retinal cell apoptosis. Free Radic Biol Med 2003;35:1500-1514.
22. Giles FJ, Fracasso PM, Kantarjian HM, et al. Phase 1 and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res 2003;27:1077-1083.
23. Gwilt PR, Tracewell WG. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet 1998;34:347-358.
24. Honda K, Casadesus G, Petersen RB, Perry G, Smith MA. Oxidative stress and redox-active iron in Alzheimer's disease. Ann NY Acad Sci 2004;1012:179-182.
25. d Annual Meeting, New Orleans, 2003. Program Number: 446.10.
26. th Annual Meeting, San Diego, 2004. Program Number 101.10.
27. th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, 2004. Control Number: 04-A-1491-ALZ.
28. Jiang Z-G, Lu X-C M, Nelson V, et al. A multi-functional cytoprotective agent that can reduce stroke-induced neurodegeneration when administered even after ischemic attack. Proc Natl Acad Sci USA 2006;103:1581-1586.
29. Jordan J, Galindo MF, Calvo S, Gonzalez-Garcia C, Cena V. Veratridine induces apoptotic death in bovine chromaffin cells through superoxide production. Br J Pharmacol 2000;130:496-1504.
30. Jordan J, Galindo MF, Tornero D, et al. Superoxide anions mediate veratridine-induced cytochrome c release and caspase activity in bovine chromaffin cells. Br J Pharmacol 2002;137:993-1000.
31. Kolberg M, Strand KR, Graff P, Andersson KK. Structure, function, and mechanism of ribonucleotide reductases. Biochim Biophys Acta 2004;1699:1-34.
32. DeConti RC, Toftness BR, Agrawal KC, et al. Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. Cancer Res 1972;32:1455-1462.
33. Kristian T, Gido G, Kuroda S, Schutz A, Siesjo BK. Calcium metabolism of focal and penumbral tissues in rats subjected to transient middle cerebral artery occlusion. Exp Brain Res 1998;120:503-509.
34. Krumam H, Mattson MP. Pivotal role of mitochondrial calcium uptake in neural cell apoptosis and necrosis J Neurochem 1999;72:529-540.
35. Lee IK, Yun BS, Kim JP, et al. p-Terphenyl curtisians protect cultured neuronal cells against glutamate neurotoxicity via iron chelation. Planta Med 2003;69:513-517.
36. Linnik MD, Miller JA, Sprinkle-Cavallo J, et al. Apoptotic DNA fragmentation in the rat cerebral cortex induced by permanent middle cerebral artery occlusion. Brain Res Mol Brain Res 1995;32:116-124.
37. Liu MC, Lin TS, Sartorelli AC. Synthesis and antitumor evaluation of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. J Med Chem 1992;3672-3677.
38. Liu S, Liu M, Peterson S, Miyake M, Vallyathan V, Liu KJ. Hydroxyl radical formation is greater in striatal core than in penumbra in a rat model of ischemic stroke. J Neurosci Res 2003;71:882-888.
39. 2 in ischemic penumbra and core are differentially affected following transient focal cerebral ischemia in rats. J Cereb Blood flow Metab 2004;24:343-349.
40. Lovejoy DB, Richardson DR. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood 2002;100:666-676.
41. th Annual Meeting, San Diego, 2004. San Diego, CA. Program Number 343.3
42. Luetjens CM, Bui NT, Sengpiel B, et al. Delayed mitochondrial dysfunction in excitotoxic neuron death: Cytochrome c release and a secondary increase in superoxide production. J Neurosci 2000;20:5715-5723.
43. Moore EC, Sartorelli AC. The inhibition of ribonucleotide reductase by α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. In: Cory JG, Cory AH, Eds. Inhibitors of ribonucleoside diphosphate reductase activity. Oxford: Pergamon Press, 1989;203-215.
44. Moore EC, Hurlert RB. The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY). In: Cory JG, Cory AH, Eds. Inhibitors of ribonucleoside diphosphate reductase activity. Oxford: Pergamon Press, 1989;165-201.
45. Murren J, Modiano M, Clairmont C, et al. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res 2003;9:4092-4100.
46. Neumar RW, Xu YA, Gada H, Guttmann RP, Siman R. Cross-talk between calpain and caspase proteolytic systems during neuronal apoptosis. J Biol Chem 2003;278:14162-14167.
47. Onteniente B, Couriaud C, Braudeau J, Benchoua A, Guegan C. The mechanisms of cell death in focal cerebral ischemia highlight neuroprotective perspectives by anti-caspase therapy. Biochem Pharmacol 2003;66:1643-1649.
48. Pike BR, Zhao X, Newcomb JK, Wang KK, Posmantur RM, Hayes RL. Temporal relationships between de novo protein synthesis, calpain and caspase 3-like protease activation, and DNA fragmentation during apoptosis in septo-hippocampal cultures. J Neurosci Res 1998;52:505-520.
49. Reichard P. The anaerobic ribonucleotide reductase from Escherichia coli. J Biol Chem 1993;268:8383-8386.
50. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341.
51. Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995;86:4295-4306.
52. Richardson DR, Milnes K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 1997;89:3025-3038.
53. Sartorelli AC, Agrawal KC, Moore EC. Mechanism of inhibition of ribonucleoside diphosphate reductase by α-(N)-heterocyclic aldehyde thiosemicarbazones. Biochem Pharmacol 1971;20:3119-3123.
54. Stubbe J. Ribonucleotide reductases: Amazing and confusing. J Biol Chem 1990;265:5329-5332.
55. Takeda E, Weber G. Role of ribonucleotide reductase in expression in the neoplastic program. Life Sci 1981;28:1007-1014.
56. Tam TF, Leung-Toung R, Li W, Wang Y, Karimian K, Spino M. Iron chelator research: past, present, and future. Curr Med Chem 2003;10:983-995.
57. Thelander L, Graslund A. Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone. Destruction of the tyrosine free radical of the enzyme in an oxygen-requiring reaction. J Biol Chem 1983;258:4063-4066.
58. Thelander L, Graslund A, Thelander M. Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: Possible regulation mechanism. Biochem Biophys Res Commun 1983;110:859-865.
59. Thelander M, Graslund A, Thelander L. Subunit M2 of mammalian ribonucleotide reductase. Characterization of a homogeneous protein isolated from M2-overproducing mouse cells. J Biol Chem 1985;260:2737-2741.
60. Thelander L, Reichard P. Reduction of ribonucleotides. Annu Rev Biochem 1979;48:133-158.
61. Torti SV, Torti FM, Whitman SP, Brechbiel MW, Park G, Planalp RP. Tumor cell cytotoxicity of a novel metal chelator. Blood 1998;92:1384-1389.
62. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, Sznol M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-h intravenous continuous infusion. J Clin Oncol 2004;22:1553-1563.
63. Weller M, Marini AM, Finiels-Marlier F, Martin B, Paul SM. MK-801 and memantine protect cultured neurons from glutamate toxicity induced by glutamate carboxypeptidase-mediated cleavage of methotrexate. Eur J Pharmacol 1993;248:303-312.
64. Wenk GL, Danysz W, Mobley SL. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol 1995;293:267-270.
65. Witt L, Yap T, Blakley RL. Regulation of ribonucleotide reductase activity and its possible exploitation in chemotherapy. Adv Enzyme Regul 1978;157-171.
66. Zipfel GJ, Babcock DJ, Lee JM, Choi DW. Neuronal apoptosis after CNS injury: The roles of glutamate and calcium. J Neurotrauma 2000;17:857-869.
67. Zhuang H, Pin S, Christen Y, Dore S. Induction of heme oxygenase 1 by Ginkgo biloba in neuronal cultures and potential implications in ischemia. Cell Mol Biol 2002;48:647-653.